FDA declines to approve gefapixant for chronic cough a second time healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
ARS Pharmaceuticals: Surprise FDA Rejection Presents Cautious Opportunity (NASDAQ:SPRY) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
FDA panel votes against gefapixant for unexplained chronic cough healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
In this interview, Dr. Kim described his response to the FDA’s decision not to approve the intranasal epinephrine spray treatment for anaphylaxis and other severe allergic reactions.
On Tuesday, The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type I), including anaphylaxis (fatal allergic reaction) for